Interestingly, S100A9 has been shown to colocalise and co-aggregate with alpha-synuclein in Lewy bodies in PD patients and in vitro studies suggest that S100A9 might alter the aggregation kinetics of alpha-synuclein40,41. This evidence concerns the gene S100A9 and Parkinson disease.